Literature DB >> 8995381

Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes.

Y M Hsu1, J Lucci, L Su, B Ehrenfels, E Garber, D Thomas.   

Abstract

CD40 ligand (CD40L), a 33-kDa type II membrane glycoprotein expressed primarily on activated CD4+ T lymphocytes, is responsible for the helper function of T cells on resting B cells in a non-antigen-dependent, non-major histocompatability complex-restricted fashion. Interaction of CD40L with its receptor CD40 induces proliferation of and isotype switching in B lymphocytes. Recently we solved the x-ray structure of recombinant soluble CD40L and showed that, similar to other members of the tumor necrosis factor family, CD40L indeed exists as a trimer. We now report that, under normal physiological conditions, CD40L molecules exist as heteromultimeric complexes. These CD40L complexes, made of the full length and smaller fragments of CD40L, are present on the cell surface of T lymphocytes and are capable of interacting with CD40 molecule. A prominent fragment with a mass of 31 kDa accounts for as much as half of the CD40L on the surface of Jurkat cells. N-terminal sequence data revealed that this fragment lacks the cytoplasmic tail. A minor 18-kDa fragment of CD40L was also characterized which lacks the cytoplasmic tail, transmembrane region, and stalk region of the extracellular domain. The presence of CD40L heteromultimeric variants implies an additional regulation of the functional activity of this ligand complex.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995381     DOI: 10.1074/jbc.272.2.911

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Functional interaction of CD154 protein with α5β1 integrin is totally independent from its binding to αIIbβ3 integrin and CD40 molecules.

Authors:  Youssef El Fakhry; Haydar Alturaihi; Daniel Yacoub; Lihui Liu; Wenyan Guo; Claire Leveillé; Daniel Jung; Lara Bou Khzam; Yahye Merhi; John A Wilkins; Hongmin Li; Walid Mourad
Journal:  J Biol Chem       Date:  2012-03-29       Impact factor: 5.157

2.  Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis.

Authors:  B Berner; G Wolf; K M Hummel; G A Müller; M A Reuss-Borst
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

3.  Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154.

Authors:  He Xu; Xiaojie Zhang; Roslyn B Mannon; Allan D Kirk
Journal:  J Clin Invest       Date:  2006-02-23       Impact factor: 14.808

4.  The role of polar interactions in the molecular recognition of CD40L with its receptor CD40.

Authors:  J Singh; E Garber; H Van Vlijmen; M Karpusas; Y M Hsu; Z Zheng; J H Naismith; D Thomas
Journal:  Protein Sci       Date:  1998-05       Impact factor: 6.725

5.  Inverse correlation between soluble CD40 ligand and soluble CD40 is absent in patients with unstable angina.

Authors:  Michitaka Tsuzuki; Itsuro Morishima; Tomohiro Yoshida; Yuzo Hayashi; Manabu Miura; Toshihisa Hirai; Toru Asai; Yasushi Numaguchi; Takahito Sone; Hideo Matsui; Kenji Okumura; Toyoaki Murohara
Journal:  Heart Vessels       Date:  2005-11       Impact factor: 2.037

6.  A Salmonella typhi OmpC fusion protein expressing the CD154 Trp140-Ser149 amino acid strand binds CD40 and activates a lymphoma B-cell line.

Authors:  Mario I Vega; Leopoldo Santos-Argumedo; Sara Huerta-Yepez; Rosendo Luría-Perez; Vianney Ortiz-Navarrete; Armado Isibasi; Cesar R González-Bonilla
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

7.  Leukocyte transfusion-associated granulocyte responses in a patient with X-linked hyper-IgM syndrome.

Authors:  T P Atkinson; C A Smith; Y M Hsu; E Garber; L Su; T H Howard; J T Prchal; M P Everson; M D Cooper
Journal:  J Clin Immunol       Date:  1998-11       Impact factor: 8.317

8.  Tropism-modification strategies for targeted gene delivery using adenoviral vectors.

Authors:  Lynda Coughlan; Raul Alba; Alan L Parker; Angela C Bradshaw; Iain A McNeish; Stuart A Nicklin; Andrew H Baker
Journal:  Viruses       Date:  2010-10-13       Impact factor: 5.818

9.  Chronic immune activation in HIV-1 infection contributes to reduced interferon alpha production via enhanced CD40:CD40 ligand interaction.

Authors:  Norbert Donhauser; Kathrin Pritschet; Martin Helm; Thomas Harrer; Philipp Schuster; Moritz Ries; Georg Bischof; Jörg Vollmer; Sigrun Smola; Barbara Schmidt
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

Review 10.  Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

Authors:  TingTing Tang; Xiang Cheng; Billy Truong; LiZhe Sun; XiaoFeng Yang; Hong Wang
Journal:  Pharmacol Ther       Date:  2020-10-20       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.